Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Depomed Executes an Exit Strategy for Its Opioid Drug

TheMotleyFool

0 0

Depomed Executes an Exit Strategy for Its Opioid Drug

After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is good news for the company because its revenue and profit have been falling this year due to waning demand for Nucynta. Does this deal make Depomed a buy?

Depomed probably wishes it had a do-over on Nucynta. It acquired the opioid painkiller from Johnson & Johnson (NYSE: JNJ) in 2015 for $1 billion shortly before opioid prescription volume fell off a cliff because of the opioid epidemic.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com